Neuropeptidomics/NNS
:/:
Mass/NN
Spectrometry-Based/JJ
Identification/NN
and/CC
Quantitation/NN
of/IN
Neuropeptides/NNS
./.
====================
Neuropeptides/NNS
produced/VBN
from/IN
prohormones/NNS
by/IN
selective/JJ
action/NN
of/IN
endopeptidases/NNS
are/VBP
vital/JJ
signaling/NN
molecules/NNS
,/,
playing/VBG
a/DT
critical/JJ
role/NN
in/IN
a/DT
variety/NN
of/IN
physiological/JJ
processes/NNS
,/,
such/JJ
as/IN
addiction/NN
,/,
depression/NN
,/,
pain/JJ
,/,
and/CC
circadian/JJ
rhythms/NNS
./.
====================
Neuropeptides/NNS
bind/VBP
to/TO
post-synaptic/JJ
receptors/NNS
and/CC
elicit/VBP
cellular/JJ
effects/NNS
like/IN
classical/JJ
neurotransmitters/NNS
./.
====================
While/IN
each/DT
neuropeptide/NN
could/MD
have/VB
its/PRP$
own/JJ
biological/JJ
function/NN
,/,
mass/NN
spectrometry/NN
(/(
MS/NN
)/)
allows/VBZ
for/IN
the/DT
identification/NN
of/IN
the/DT
precise/JJ
molecular/JJ
forms/NNS
of/IN
each/DT
peptide/NN
without/IN
a/DT
priori/JJ
knowledge/NN
of/IN
the/DT
peptide/NN
identity/NN
and/CC
for/IN
the/DT
quantitation/NN
of/IN
neuropeptides/NNS
in/IN
different/JJ
conditions/NNS
of/IN
the/DT
samples/NNS
./.
====================
MS-based/JJ
neuropeptidomics/NNS
approaches/NNS
have/VBP
been/VBN
applied/VBN
to/TO
various/JJ
animal/JJ
models/NNS
and/CC
conditions/NNS
to/TO
characterize/VB
and/CC
quantify/RB
novel/JJ
neuropeptides/NNS
,/,
as/IN
well/RB
as/IN
known/VBN
neuropeptides/NNS
,/,
advancing/VBG
our/PRP$
understanding/NN
of/IN
nervous/JJ
system/NN
function/NN
over/IN
the/DT
past/NN
decade/NN
./.
====================
Here/RB
,/,
we/PRP
will/MD
present/JJ
an/DT
overview/NN
of/IN
neuropeptides/NNS
and/CC
MS-based/JJ
neuropeptidomic/JJ
strategies/NNS
for/IN
the/DT
identification/NN
and/CC
quantitation/NN
of/IN
neuropeptides/NNS
./.
====================
Neuropeptides/NNS
,/,
which/WDT
signal/NN
between/IN
neurons/NNS
,/,
are/VBP
known/VBN
to/TO
be/VB
involved/VBN
in/IN
a/DT
variety/NN
of/IN
physiological/JJ
processes/NNS
,/,
including/VBG
addiction/NN
,/,
depression/NN
,/,
hunger/JJR
,/,
pain/JJ
,/,
fear/JJ
,/,
anxiety/NN
,/,
and/CC
circadian/JJ
rhythms/NNS
[/(
12/CD
]/)
./.
====================
Neuropeptides/NNS
are/VBP
3–100/CD
amino/NN
acid/NN
residues/NNS
long/JJ
and/CC
up/IN
to/TO
50/CD
times/NNS
larger/JJR
than/IN
classic/JJ
neurotransmitters/NNS
[/(
3/CD
]/)
./.
====================
The/DT
term/NN
``/NN
neuropeptides/NNS
''/CD
was/VBD
first/JJ
introduced/JJ
by/IN
De/JJ
Wied/JJ
[/(
4/CD
]/)
in/IN
1971/CD
to/TO
describe/VB
an/DT
endogenous/JJ
peptide/NN
synthesized/VBN
in/IN
nerve/NN
cells/NNS
./.
====================
While/IN
peptide/NN
hormones/NNS
are/VBP
also/RB
considered/VBN
important/JJ
intercellular/JJ
signaling/NN
molecules/NNS
,/,
there/EX
are/VBP
differences/NNS
between/IN
neuropeptides/NNS
and/CC
peptide/NN
hormones/NNS
./.
====================
That/DT
is/VBZ
,/,
neuropeptides/NNS
are/VBP
secreted/VBN
from/IN
neuronal/JJ
cells/NNS
(/(
primarily/RB
neurons/NNS
but/CC
also/RB
glia/NN
for/IN
some/DT
peptides/NNS
)/)
and/CC
signal/NN
to/TO
neighboring/JJ
cells/NNS
(/(
primarily/RB
neurons/NNS
)/)
,/,
whereas/IN
peptide/NN
hormones/NNS
are/VBP
secreted/VBN
from/IN
neuroendocrine/JJ
cells/NNS
and/CC
act/VBP
on/IN
distant/JJ
tissues/NNS
by/IN
traveling/VBG
through/IN
the/DT
blood/NN
[/(
25/CD
]/)
./.
====================
Approximately/RB
100/CD
different/JJ
neuropeptides/NNS
are/VBP
currently/RB
known/VBN
to/TO
function/VB
in/IN
cell-to-cell/JJ
signaling/NN
(/(
http/NN
:/:
//www.neuropeptides.nl/JJ
)/)
./.
====================
Neuropeptides/NNS
bind/VBP
to/TO
post-synaptic/JJ
receptors/NNS
and/CC
elicit/VBP
cellular/JJ
responses/NNS
like/IN
classical/JJ
neurotransmitters/NNS
./.
====================
Neuropeptides/NNS
are/VBP
produced/VBN
from/IN
precursor/NN
proteins/NNS
(/(
or/CC
prohormones/NNS
)/)
by/IN
a/DT
series/NN
of/IN
enzymatic/JJ
processing/NN
steps/NNS
./.
====================
The/DT
neuropeptide/NN
precursors/NNS
generally/RB
do/VBP
not/RB
have/VB
functions/NNS
on/IN
their/PRP$
own/JJ
,/,
requiring/VBG
processing/NN
to/TO
generate/VB
the/DT
active/JJ
forms/NNS
./.
====================
The/DT
precursors/NNS
are/VBP
synthesized/VBN
on/IN
ribosomes/NNS
at/IN
the/DT
endoplasmic/JJ
reticulum/NN
and/CC
processed/VBN
through/IN
the/DT
Golgi/NN
[/(
5/CD
]/)
./.
====================
When/WRB
the/DT
NH2-terminal/JJ
signal/NN
peptide/NN
of/IN
the/DT
neuropeptide/NN
precursors/NNS
is/VBZ
cleaved/VBN
by/IN
signal/NN
peptidase/NN
,/,
the/DT
precursors/NNS
are/VBP
routed/VBN
to/TO
the/DT
Golgi/NNP
apparatus/NN
and/CC
packaged/JJ
into/IN
dense-core/RB
secretory/JJ
vesicles/NNS
together/RB
with/IN
processing/NN
proteases/NNS
,/,
termed/VBN
convertases/VBZ
./.
====================
Most/JJS
neuropeptide/NN
precursors/NNS
are/VBP
first/JJ
processed/VBN
by/IN
endopeptidases/NNS
,/,
including/VBG
prohormone/NN
convertase/NN
1/CD
(/(
also/RB
known/VBN
as/IN
prohormone/RB
convertase/NN
3/CD
)/)
and/CC
prohormone/NN
convertase/NN
2/CD
and/CC
,/,
to/TO
a/DT
lesser/JJR
extent/NN
,/,
prohormone/proprotein/NN
convertase/NN
5A/NN
(/(
also/RB
known/VBN
as/IN
prohormone/proprotein/JJ
convertase/NN
6A/NN
)/)
[/(
6/CD
]/)
./.
====================
The/DT
endopeptidases/NNS
typically/RB
cleave/JJ
at/IN
pairs/NNS
of/IN
basic/JJ
amino/NN
acids/NNS
,/,
usually/RB
Lys-Arg/NN
(/(
KR/NN
)/)
or/CC
Arg-Arg/NN
(/(
RR/NN
)/)
sites/NNS
,/,
but/CC
on/IN
occasion/NN
,/,
the/DT
basic/JJ
amino/NN
acids/NNS
are/VBP
separated/VBN
by/IN
2/CD
,/,
4/CD
,/,
or/CC
6/CD
other/JJ
amino/NN
acids/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
next/JJ
stage/NN
of/IN
processing/NN
is/VBZ
the/DT
removal/NN
of/IN
C-terminal/JJ
basic/JJ
residues/NNS
in/IN
the/DT
mature/JJ
secretory/JJ
vesicle/NN
./.
====================
Carboxypeptidase/NN
E/NN
is/VBZ
the/DT
exopeptidase/NN
primarily/RB
responsible/JJ
for/IN
removing/VBG
the/DT
C-terminal/JJ
basic/JJ
residues/NNS
,/,
and/CC
carboxypeptidase/NN
D/NN
has/VBZ
also/RB
been/VBN
shown/VBN
to/TO
act/VB
in/IN
this/DT
role/NN
./.
====================
After/IN
removal/NN
of/IN
the/DT
C-terminal/JJ
basic/JJ
residues/NNS
,/,
other/JJ
enzymes/NNS
perform/VBP
additional/JJ
post-translational/JJ
modifications/NNS
(/(
PTMs/NNS
)/)
,/,
such/JJ
as/IN
amidation/NN
,/,
acetylation/NN
,/,
phosphorylation/NN
,/,
sulfation/NN
,/,
and/CC
glycosylation/NN
[/(
6/CD
]/)
./.
====================
For/IN
example/NN
,/,
peptides/NNS
with/IN
a/DT
C-terminal/JJ
glycine/NN
are/VBP
typically/RB
converted/VBN
to/TO
the/DT
amide/NN
by/IN
peptidyl-α-amidating/VBG
monooxygnenase/NN
[/(
7/CD
]/)
,/,
and/CC
tyrosine/NN
sulfation/NN
is/VBZ
known/VBN
to/TO
be/VB
mediated/VBN
by/IN
tyrosylprotein/NN
sulfotransferase/NN
[/(
8/CD
]/)
./.
====================
These/DT
final/JJ
bioactive/JJ
forms/NNS
of/IN
the/DT
peptides/NNS
are/VBP
stored/VBN
within/IN
secretory/JJ
vesicles/NNS
that/DT
are/VBP
accumulated/VBN
within/IN
the/DT
cells/NNS
./.
====================
When/WRB
the/DT
cells/NNS
are/VBP
stimulated/VBN
,/,
the/DT
secretory/JJ
vesicles/NNS
are/VBP
known/VBN
to/TO
fuse/VB
with/IN
the/DT
cellular/JJ
membrane/NN
to/TO
release/VB
the/DT
neuropeptides/NNS
into/IN
the/DT
extracellular/JJ
environment/NN
[/(
2/CD
]/)
./.
====================
The/DT
secreted/VBN
neuropeptides/NNS
can/MD
interact/VB
with/IN
receptors/NNS
containing/VBG
specific/JJ
binding/NN
sites/NNS
./.
====================
The/DT
receptors/NNS
are/VBP
often/RB
G-protein-coupled/JJ
receptors/NNS
./.
====================
The/DT
interaction/NN
of/IN
the/DT
neuropeptides/NNS
with/IN
the/DT
receptors/NNS
causes/VBZ
a/DT
conformational/JJ
change/NN
in/IN
the/DT
receptor/NN
,/,
resulting/VBG
in/IN
the/DT
production/NN
of/IN
a/DT
cellular/JJ
response/NN
through/IN
a/DT
variety/NN
of/IN
mechanisms/NNS
,/,
depending/VBG
on/IN
the/DT
type/NN
of/IN
receptor/NN
./.
====================
While/IN
a/DT
single/JJ
neuropeptide/NN
precursor/NN
often/RB
produces/VBZ
multiple/JJ
neuropeptides/NNS
,/,
the/DT
proteolytic/JJ
processing/NN
of/IN
the/DT
precursor/NN
protein/NN
occurs/VBZ
in/IN
a/DT
tissue-specific/JJ
and/CC
even/RB
region-specific/JJ
manner/NN
./.
====================
A/DT
classic/JJ
example/NN
is/VBZ
the/DT
processing/NN
of/IN
the/DT
precursor/NN
proopiomelanocortin/NN
in/IN
the/DT
pituitary/JJ
./.
====================
In/IN
the/DT
anterior/JJ
lobe/NN
of/IN
the/DT
pituitary/JJ
,/,
the/DT
precursor/NN
is/VBZ
converted/VBN
into/IN
adrenocorticotropic/JJ
hormone/NN
(/(
ACTH/NN
)/)
,/,
which/WDT
binds/VBZ
to/TO
several/JJ
subtypes/NNS
of/IN
melanocortin/NN
receptors/NNS
,/,
such/JJ
as/IN
MC2R/NN
,/,
located/JJ
in/IN
the/DT
adrenal/JJ
gland/NN
;/:
this/DT
receptor/NN
controls/NNS
the/DT
production/NN
of/IN
glucocorticoids/NNS
(/(
cortisol/NN
)/)
[/(
910/CD
]/)
./.
====================
In/IN
the/DT
intermediate/JJ
lobe/NN
of/IN
the/DT
pituitary/JJ
and/CC
also/RB
in/IN
the/DT
brain/NN
,/,
ACTH/NN
is/VBZ
further/RBR
processed/VBN
into/IN
alpha-melanocyte-stimulating/JJ
hormone/NN
,/,
which/WDT
binds/VBZ
to/TO
melanocortin/NN
receptors/NNS
with/IN
completely/RB
different/JJ
affinities/NNS
[/(
11/CD
]/)
./.
====================
The/DT
PTMs/NNS
can/MD
also/RB
regulate/VBP
the/DT
bioactivity/NN
and/CC
stability/NN
of/IN
the/DT
neuropeptides/NNS
and/CC
therefore/RB
affect/VB
the/DT
binding/NN
affinities/NNS
of/IN
the/DT
neuropeptides/NNS
for/IN
the/DT
receptors/NNS
./.
====================
For/IN
example/NN
,/,
acetylation/NN
of/IN
the/DT
N-terminus/NN
of/IN
β-endorphin/NN
removes/VBZ
the/DT
ability/NN
of/IN
the/DT
peptide/NN
to/TO
stimulate/VB
opioid/JJ
receptors/NNS
and/CC
to/TO
produce/VB
analgesia/NN
[/(
6/CD
]/)
./.
====================
Conversely/RB
,/,
octanoylation/NN
of/IN
the/DT
peptide/NN
ghrelin/NN
on/IN
a/DT
serine/NN
residue/NN
is/VBZ
essential/JJ
for/IN
the/DT
binding/NN
of/IN
the/DT
peptide/NN
to/TO
its/PRP$
receptor/NN
[/(
12/CD
]/)
./.
====================
Although/IN
the/DT
various/JJ
aspects/NNS
of/IN
peptide/NN
synthesis/NN
,/,
including/VBG
PTMs/NNS
,/,
lead/VBP
to/TO
an/DT
increase/NN
in/IN
neuropeptide/NN
complexity/NN
,/,
unveiling/VBG
new/JJ
peptides/NNS
and/CC
unreported/JJ
peptide/NN
properties/NNS
is/VBZ
critical/JJ
to/TO
advancing/VBG
our/PRP$
understanding/NN
of/IN
nervous/JJ
system/NN
function/NN
./.
====================
While/IN
neuropeptides/NNS
are/VBP
involved/VBN
in/IN
a/DT
wide/JJ
range/NN
of/IN
physiological/JJ
processes/NNS
,/,
including/VBG
hunger/JJR
,/,
food/NN
intake/JJ
,/,
body/NN
weight/NN
regulation/NN
,/,
and/CC
circadian/JJ
rhythms/NNS
,/,
it/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
dysregulation/NN
of/IN
neuropeptides/NNS
often/RB
results/VBZ
in/IN
a/DT
variety/NN
of/IN
neurological/JJ
disorders/NNS
[/(
131415/CD
]/)
./.
====================
Epilepsy/NN
is/VBZ
a/DT
common/JJ
neurological/JJ
disorder/NN
characterized/VBN
by/IN
recurrent/JJ
seizures/NNS
./.
====================
Neuropeptides/NNS
,/,
such/JJ
as/IN
arginine-vasopressin/RB
,/,
corticotropin-releasing/VBG
factor/NN
(/(
CRF/NN
)/)
,/,
enkephalin/NN
,/,
β-endorphin/IN
,/,
pituitary/JJ
adenylate/JJ
cyclase-activating/VBG
polypeptide/NN
(/(
PACAP/NN
)/)
,/,
and/CC
tachykinins/NNS
,/,
were/VBD
shown/VBN
to/TO
have/VB
proconvulsive/JJ
effects/NNS
,/,
whereas/IN
other/JJ
neuropeptides/NNS
,/,
like/IN
ACTH/NN
,/,
angiotensin/NN
,/,
cholecystokinin/NN
,/,
somatostatin/RB
,/,
and/CC
thyrotropin-releasing/VBG
hormone/NN
,/,
were/VBD
able/JJ
to/TO
suppress/VB
seizures/NNS
in/IN
the/DT
brain/NN
[/(
16/CD
]/)
./.
====================
In/IN
addition/NN
,/,
neuropeptides/NNS
,/,
such/JJ
as/IN
dynorphin/NN
and/CC
substance/NN
P/NN
,/,
were/VBD
shown/VBN
to/TO
be/VB
involved/VBN
in/IN
the/DT
pathophysiology/NN
of/IN
Parkinson/NN
's/POS
disease/NN
,/,
which/WDT
is/VBZ
a/DT
neurodegenerative/JJ
disease/NN
with/IN
motor/NN
and/CC
non-motor/JJ
symptoms/NNS
[/(
17/CD
]/)
./.
====================
Progression/NN
to/TO
addiction/NN
is/VBZ
also/RB
known/VBN
to/TO
be/VB
influenced/VBN
by/IN
several/JJ
peptidergic/JJ
neuromodulators/NNS
./.
====================
A/DT
few/JJ
orexigenic/JJ
neuropeptides/NNS
,/,
including/VBG
galanin/NN
,/,
enkephalin/NN
,/,
and/CC
orexin/hypocretin/NN
,/,
were/VBD
shown/VBN
to/TO
have/VB
a/DT
positive/JJ
feedback/NN
relationship/NN
to/TO
alcohol/NN
,/,
while/IN
other/JJ
hypothalamic/JJ
neuropeptides/NNS
,/,
such/JJ
as/IN
dynorphin/IN
,/,
CRF/NN
,/,
and/CC
melanocortins/NNS
,/,
showed/VBD
a/DT
negative/JJ
feedback/NN
relationship/NN
to/TO
alcohol/NN
intake/JJ
./.
====================
Dysregulation/NN
of/IN
these/DT
multiple/JJ
neuropeptides/NNS
is/VBZ
assumed/VBN
to/TO
result/VB
in/IN
alcohol/NN
addiction/NN
[/(
18/CD
]/)
./.
====================
There/EX
was/VBD
also/RB
a/DT
report/NN
that/IN
neuropeptides/NNS
,/,
such/JJ
as/IN
substance/RB
P/NN
,/,
calcitonin/NN
gene-related/VBN
peptides/NNS
,/,
vasoactive/JJ
intestinal/JJ
peptide/PACAP/NN
,/,
and/CC
neuropeptide/NN
Y/NN
(/(
NPY/NN
)/)
,/,
are/VBP
associated/VBN
with/IN
regulation/NN
of/IN
cutaneous/JJ
immune/JJ
responses/NNS
and/CC
tissue/NN
maintenance/NN
and/CC
repair/NN
./.
====================
Due/IN
to/TO
these/DT
diverse/JJ
functions/NNS
of/IN
neuropeptides/NNS
,/,
neuropeptides/NNS
and/CC
neuropeptide/NN
receptors/NNS
have/VBP
been/VBN
drug/NN
targets/NNS
for/IN
the/DT
treatment/NN
of/IN
neurological/JJ
disorders/NNS
[/(
319/CD
]/)
./.
====================
Traditional/JJ
methods/NNS
of/IN
neuropeptide/NN
analysis/NN
====================
Traditionally/RB
,/,
the/DT
analysis/NN
of/IN
neuropeptides/NNS
was/VBD
performed/VBN
by/IN
Edman/NN
sequencing/NN
,/,
in/IN
which/WDT
the/DT
N-terminal/JJ
amino/NN
acid/NN
is/VBZ
sequentially/RB
removed/VBD
./.
====================
The/DT
method/NN
was/VBD
developed/VBN
by/IN
Edman/NN
in/IN
1950/CD
and/CC
is/VBZ
used/VBN
for/IN
neuropeptide/NN
sequencing/NN
in/IN
many/JJ
different/JJ
species—for/IN
example/NN
,/,
NPY/NN
in/IN
the/DT
porcine/NN
brain/NN
[/(
20/CD
]/)
and/CC
gonadotropin-releasing/VBG
hormone/NN
in/IN
the/DT
dogfish/JJ
brain/NN
[/(
21/CD
]/)
./.
====================
However/RB
,/,
analysis/NN
by/IN
this/DT
method/NN
is/VBZ
slow/JJ
and/CC
does/VBZ
not/RB
allow/VB
for/IN
the/DT
sequencing/NN
of/IN
neuropeptides/NNS
containing/VBG
N-terminal/JJ
PTMs/NNS
[/(
22/CD
]/)
./.
====================
Immunological/JJ
techniques/NNS
,/,
such/JJ
as/IN
radioimmunoassay/NN
(/(
RIA/NN
)/)
and/CC
immunohistochemistry/NN
(/(
IHC/NN
)/)
,/,
have/VBP
been/VBN
used/VBN
for/IN
measuring/VBG
relative/JJ
neuropeptide/NN
levels/NNS
and/CC
spatial/JJ
localization/NN
./.
====================
RIA/NN
has/VBZ
been/VBN
a/DT
popular/JJ
tool/NN
to/TO
quantify/VB
neuropeptides/NNS
in/IN
biological/JJ
samples/NNS
,/,
such/JJ
as/IN
NPY/NN
[/(
23/CD
]/)
and/CC
galanin/NN
in/IN
the/DT
rat/NN
brain/NN
[/(
24/CD
]/)
./.
====================
Although/IN
RIA/NN
is/VBZ
a/DT
relatively/RB
sensitive/JJ
technique/NN
capable/JJ
of/IN
absolute/JJ
quantification/NN
of/IN
peptide/NN
levels/NNS
,/,
it/PRP
is/VBZ
not/RB
always/RB
specific/JJ
for/IN
a/DT
single-peptide/JJ
form/VBP
because/IN
of/IN
its/PRP$
antibody-based/JJ
detection/NN
method/NN
./.
====================
In/IN
addition/NN
,/,
unless/IN
specific/JJ
antibodies/NNS
are/VBP
available/JJ
for/IN
the/DT
different/JJ
isoforms/NNS
,/,
RIAs/NNS
do/VBP
not/RB
distinguish/VB
between/IN
these/DT
modifications/NNS
./.
====================
IHC/NN
has/VBZ
provided/VBN
essential/JJ
information/NN
regarding/VBG
the/DT
localization/NN
of/IN
neuropeptides/NNS
within/IN
the/DT
complexity/NN
of/IN
the/DT
brain/NN
structure/NN
,/,
improving/VBG
our/PRP$
understanding/NN
of/IN
the/DT
distribution/NN
of/IN
peptides/NNS
./.
====================
However/RB
,/,
IHC/NN
does/VBZ
not/RB
report/VB
the/DT
actual/JJ
size/NN
or/CC
full/JJ
identity/NN
of/IN
the/DT
peptide/NN
,/,
including/VBG
PTMs/NNS
./.
====================
In/IN
addition/NN
,/,
these/DT
antibody-based/JJ
methods/NNS
require/VBP
a/DT
priori/JJ
knowledge/NN
of/IN
a/DT
potential/JJ
neuropeptide/JJ
in/IN
order/NN
to/TO
generate/VB
antibodies/NNS
specific/JJ
to/TO
the/DT
neuropeptides/NNS
and/CC
only/RB
detect/VB
peptide/NN
sequences/NNS
with/IN
known/VBN
structures/NNS
./.
====================
Mass/NN
Spectrometry-Based/JJ
Peptidomics/NNS
====================
In/IN
contrast/NN
to/TO
immuno-based/VBN
methods/NNS
,/,
mass/NN
spectrometry/NN
(/(
MS/NN
)/)
enables/VBZ
one/CD
to/TO
detect/VB
and/CC
identify/VBP
the/DT
precise/JJ
forms/NNS
of/IN
neuropeptides/NNS
without/IN
a/DT
priori/JJ
knowledge/NN
of/IN
the/DT
peptide/NN
's/POS
identity/NN
,/,
resulting/VBG
in/IN
the/DT
identification/NN
of/IN
previously/RB
unknown/JJ
neuropeptides/NNS
./.
====================
MS/NN
has/VBZ
been/VBN
used/VBN
to/TO
identify/VB
and/CC
characterize/VBP
hundreds/VBZ
of/IN
endogenous/JJ
peptides/NNS
in/IN
various/JJ
animals/NNS
[/(
2526272829/CD
]/)
./.
====================
The/DT
high-throughput/JJ
discovery/NN
of/IN
neuropeptides/NNS
based/VBN
on/IN
MS/NN
has/VBZ
made/VBN
up/IN
the/DT
field/NN
of/IN
peptidomics/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
[/(
630313233/CD
]/)
./.
====================
While/IN
typical/JJ
proteomic/JJ
analysis/NN
involves/VBZ
the/DT
digestion/NN
of/IN
proteins/NNS
using/VBG
proteases/NNS
,/,
such/JJ
as/IN
trypsin/NN
,/,
to/TO
generate/VB
peptides/NNS
that/IN
can/MD
be/VB
readily/RB
sequenced/VBN
by/IN
tandem/JJ
mass/NN
spectrometry/NN
(/(
MS/MS/NN
)/)
,/,
peptidomics/NNS
focuses/VBZ
on/IN
the/DT
analysis/NN
of/IN
the/DT
native/JJ
peptide/NN
forms/NNS
,/,
including/VBG
PTMs/NNS
,/,
without/IN
using/VBG
digestive/JJ
enzymes/NNS
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
identify/VB
and/CC
characterize/VBP
as/IN
many/JJ
neuropeptides/NNS
as/IN
possible/JJ
,/,
because/IN
each/DT
peptide/NN
can/MD
have/VB
its/PRP$
own/JJ
biological/JJ
function/NN
./.
====================
While/IN
MS-based/JJ
peptidomics/NNS
can/MD
be/VB
utilized/VBN
to/TO
characterize/VB
a/DT
large/JJ
number/NN
of/IN
neuropeptides/NNS
simultaneously/RB
,/,
it/PRP
can/MD
be/VB
also/RB
applied/VBD
to/TO
the/DT
quantification/NN
of/IN
individual/JJ
neuropeptides/NNS
./.
====================
Sample/NN
Preparation/NN
for/IN
Peptidomics/NNS
Experiment/JJ
====================
Although/IN
MS/NN
allows/VBZ
the/DT
identification/NN
of/IN
a/DT
large/JJ
number/NN
of/IN
neuropeptides/NNS
in/IN
a/DT
high-throughput/JJ
manner/NN
,/,
sample/JJ
preparation/NN
prior/JJ
to/TO
MS/NN
is/VBZ
a/DT
critical/JJ
step/NN
that/IN
affects/VBZ
peptide/NN
identification/NN
coverage/NN
in/IN
peptidomics/NNS
experiments/NNS
./.
====================
When/WRB
the/DT
animal/NN
is/VBZ
sacrificed/VBN
and/CC
the/DT
brain/NN
tissue/NN
of/IN
interest/NN
is/VBZ
obtained/VBN
,/,
proteases/NNS
rapidly/RB
degrade/VBP
larger/JJR
proteins/NNS
into/IN
smaller/JJR
peptides/NNS
that/IN
fall/VBP
into/IN
the/DT
mass/NN
range/NN
of/IN
neuropeptides/NNS
./.
====================
The/DT
presence/NN
of/IN
degraded/VBN
products/NNS
derived/VBN
from/IN
highly/RB
abundant/JJ
proteins/NNS
often/RB
complicates/VBZ
the/DT
MS/NN
analysis/NN
and/CC
interferes/VBZ
with/IN
the/DT
identification/NN
of/IN
less/RBR
abundant/JJ
neuropeptides/NNS
./.
====================
Different/JJ
techniques/NNS
,/,
including/VBG
focused/VBN
microwave/NNS
irradiation/NN
before/IN
decapitation/NN
,/,
microwave/VBP
irradiation/NN
after/IN
decapitation/NN
,/,
and/CC
boiling/VBG
the/DT
tissue/NN
immediately/RB
after/IN
decapitation/NN
,/,
have/VBP
been/VBN
used/VBN
in/IN
order/NN
to/TO
inactivate/VB
the/DT
proteases/NNS
responsible/JJ
for/IN
the/DT
high/JJ
background/NN
of/IN
protein/NN
degradation/NN
fragments/NNS
[/(
323435363738/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
the/DT
procedures/NNS
of/IN
protease/NN
deactivation/NN
,/,
peptide/NN
extraction/NN
and/CC
subsequent/JJ
treatment/NN
are/VBP
other/JJ
steps/NNS
that/IN
affect/VBP
the/DT
number/NN
of/IN
identified/VBN
neuropeptides/NNS
./.
====================
The/DT
use/NN
of/IN
different/JJ
solvents/NNS
and/CC
procedures/NNS
can/MD
affect/VB
the/DT
peptide/NN
profiles/NNS
detectable/JJ
in/IN
brain/NN
tissue/NN
./.
====================
Che/DT
et/FW
al/JJ
./.
====================
[/(
31/CD
]/)
compared/VBN
different/JJ
extraction/NN
conditions/NNS
for/IN
the/DT
recovery/NN
of/IN
neuropeptides/NNS
from/IN
mouse/NN
hypothalamus/NN
./.
====================
They/PRP
found/VBN
that/IN
sonication/NN
and/CC
heating/JJ
in/IN
water/NN
(/(
70℃/CD
for/IN
20/CD
min/NN
)/)
,/,
followed/VBN
by/IN
cold/JJ
acid/NN
and/CC
centrifugation/NN
,/,
enabled/VBD
the/DT
efficient/JJ
extraction/NN
of/IN
many/JJ
neuropeptides/NNS
without/IN
the/DT
formation/NN
of/IN
the/DT
protein/NN
degradation/NN
fragments/NNS
seen/VBN
with/IN
hot/JJ
acid/NN
extractions/NNS
./.
====================
Bora/NN
et/FW
al/JJ
./.
====================
[/(
39/CD
]/)
and/CC
Lee/NNP
et/FW
al/JJ
./.
====================
[/(
37/CD
]/)
also/RB
showed/VBD
that/IN
multiple/JJ
stages/NNS
of/IN
peptide/NN
extraction/NN
,/,
including/VBG
boiling/VBG
water/NN
,/,
acidified/VBN
acetone/NN
,/,
and/CC
acetic/JJ
acid/NN
,/,
were/VBD
able/JJ
to/TO
maximize/VB
the/DT
number/NN
of/IN
identified/VBN
neuropeptides/NNS
from/IN
their/PRP$
respective/JJ
analyses/NNS
of/IN
supraoptic/JJ
nucleus/NN
and/CC
suprachiasmatic/JJ
nucleus/NN
(/(
SCN/NN
)/)
samples/NNS
in/IN
the/DT
rat/NN
brain/NN
./.
====================
MS/NN
Analysis/NN
====================
After/IN
sample/NN
processing/NN
,/,
the/DT
extracted/VBN
peptides/NNS
are/VBP
subjected/VBN
to/TO
MS/NN
analysis/NN
./.
====================
A/DT
mass/NN
spectrometer/NN
consists/VBZ
of/IN
an/DT
ionization/NN
source/NN
,/,
a/DT
mass/NN
analyzer/NN
separating/VBG
the/DT
ions/NNS
based/VBN
on/IN
their/PRP$
mass-to-charge/JJ
ratio/NN
(/(
m/z/NN
)/)
,/,
and/CC
a/DT
detector/NN
recording/VBG
the/DT
number/NN
of/IN
ions/NNS
at/IN
each/DT
m/z/NN
value/NN
./.
====================
Two/CD
commonly/RB
used/VBN
types/NNS
of/IN
ionization/NN
are/VBP
electrospray/NN
ionization/NN
(/(
ESI/NN
)/)
and/CC
matrix-assisted/VBD
laser/NN
desorption/ionization/NN
(/(
MALDI/NN
)/)
./.
====================
While/IN
each/DT
approach/NN
has/VBZ
its/PRP$
own/JJ
advantages/NNS
,/,
MALDI/NN
is/VBZ
more/RBR
tolerant/JJ
to/TO
the/DT
presence/NN
of/IN
salts/NNS
./.
====================
Thus/RB
,/,
MALDI/NN
is/VBZ
often/RB
applied/VBN
to/TO
direct/JJ
tissue/NN
profiling/VBG
or/CC
molecular/JJ
ion/NN
imaging/NN
from/IN
tissue/NN
sections/NNS
./.
====================
Direct/JJ
tissue/NN
sample/NN
analysis/NN
by/IN
MALDI-based/JJ
MS/NN
is/VBZ
usually/RB
performed/VBN
by/IN
a/DT
simple/JJ
sequence/NN
of/IN
steps/NNS
,/,
which/WDT
include/VBP
placing/VBG
the/DT
tissue/NN
of/IN
interest/JJ
on/IN
the/DT
MALDI/NN
plate/VBP
,/,
applying/VBG
a/DT
droplet/JJ
of/IN
matrix/NN
,/,
and/CC
irradiating/VBG
the/DT
co-crystallized/VBN
tissue/NN
to/TO
cause/VB
desorption/ionization/NN
of/IN
the/DT
peptides/NNS
[/(
30/CD
]/)
./.
====================
MALDI/NN
imaging/NN
provides/VBZ
valuable/JJ
information/NN
pertaining/VBG
to/TO
the/DT
spatial/JJ
localization/NN
of/IN
neuropeptides/NNS
[/(
40/CD
]/)
./.
====================
Although/IN
MALDI-MS/NN
can/MD
be/VB
interfaced/JJ
with/IN
separation/NN
strategies/NNS
,/,
such/JJ
as/IN
liquid/JJ
chromatography/NN
(/(
LC/NN
)/)
and/CC
capillary/JJ
electrophoresis/NN
,/,
ESI-MS/NN
can/MD
be/VB
coupled/VBN
more/RBR
easily/RB
with/IN
the/DT
separation/NN
methods/NNS
,/,
because/IN
the/DT
ions/NNS
are/VBP
produced/VBN
as/IN
an/DT
aerosol/NN
from/IN
the/DT
liquid/JJ
phase/NN
with/IN
a/DT
high/JJ
voltage/NN
in/IN
ESI/NN
./.
====================
The/DT
introduction/NN
of/IN
a/DT
nano-electrospray/JJ
,/,
based/VBN
on/IN
capillary/JJ
LC/NN
,/,
coupled/VBN
to/TO
MS/NN
,/,
significantly/RB
increases/VBZ
the/DT
sensitivity/NN
in/IN
LC-ESI-MS/NN
,/,
and/CC
furthermore/RB
,/,
the/DT
preferred/JJ
formation/NN
of/IN
multiple-charge/JJ
states/NNS
in/IN
ESI/NN
allows/VBZ
for/IN
more/RBR
comprehensive/JJ
MS/MS/NN
fragmentation/NN
data/NNS
./.
====================
MS/NN
Data/NNS
Analysis/NN
for/IN
Neuropeptide/NN
Identification/NN
====================
While/IN
neuropeptides/NNS
can/MD
be/VB
identified/VBN
by/IN
comparing/VBG
experimental/JJ
peptide/NN
masses/NNS
obtained/VBN
from/IN
MS/NN
data/NNS
against/IN
a/DT
list/NN
of/IN
known/VBN
neuropeptide/NN
masses/NNS
,/,
they/PRP
are/VBP
typically/RB
identified/VBN
with/IN
both/DT
MS/NN
and/CC
MS/MS/NN
fragmentation/NN
data/NNS
./.
====================
While/IN
collision-induced/JJ
dissociation/NN
is/VBZ
widely/RB
used/VBN
for/IN
peptide/NN
identification/NN
,/,
other/JJ
fragmentation/NN
methods/NNS
,/,
such/JJ
as/IN
higher/JJR
energy/NN
collision/NN
dissociation/NN
and/CC
electron/NN
transfer/NN
dissociation/NN
,/,
have/VBP
recently/RB
improved/VBN
the/DT
identification/NN
capability/NN
of/IN
peptides/NNS
and/CC
PTM/NN
localization/NN
[/(
414243/CD
]/)
./.
====================
The/DT
automated/JJ
identification/NN
of/IN
neuropeptides/NNS
based/VBN
on/IN
their/PRP$
MS/NN
and/CC
MS/MS/NN
data/NNS
is/VBZ
pursued/VBN
by/IN
using/VBG
proteomic-based/VBN
search/VBP
engines/VBZ
,/,
such/JJ
as/IN
Mascot/JJ
,/,
SEQUEST/NN
,/,
X/NN
!/CD
Tandem/JJ
,/,
Peaks/NNS
Studio/NN
,/,
and/CC
ProSightPC/NN
[/(
3744454647/CD
]/)
./.
====================
Since/IN
peptidomics/NNS
searches/VBZ
typically/RB
employ/JJ
criteria/NNS
,/,
such/JJ
as/IN
no/DT
enzymatic/JJ
cleavage/NN
and/CC
various/JJ
common/JJ
modifications/NNS
(/(
e.g./FW
,/,
N-terminal/JJ
acetylation/NN
and/CC
C-terminal/JJ
amidation/NN
)/)
,/,
they/PRP
often/RB
require/VBP
a/DT
larger/RBR
search/VB
space/NN
and/CC
longer/RBR
search/VBP
times/NNS
for/IN
peptide/NN
identification/NN
./.
====================
Several/JJ
neuropeptide/JJ
prohormone/NN
databases/NNS
,/,
including/VBG
SwePep/JJ
,/,
have/VBP
been/VBN
constructed/VBN
to/TO
facilitate/VB
neuropeptide/NN
identification/NN
,/,
and/CC
cleavage/NN
prediction/NN
programs/NNS
,/,
such/JJ
as/IN
NeuroPred/VBN
,/,
were/VBD
developed/VBN
to/TO
predict/VB
cleavage/NN
sites/NNS
in/IN
prohormones/NNS
and/CC
to/TO
provide/VB
the/DT
masses/NNS
of/IN
the/DT
resulting/VBG
peptides/NNS
[/(
4849/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
the/DT
database/NN
search/VBP
strategies/NNS
,/,
neuropeptides/NNS
can/MD
be/VB
also/RB
identified/VBD
by/IN
de/FW
novo/FW
sequencing/NN
,/,
especially/RB
when/WRB
the/DT
species/NNS
of/IN
interest/NN
does/VBZ
not/RB
have/VB
a/DT
sequenced/VBN
genome/NN
./.
====================
While/IN
peptide/NN
spectra/NN
are/VBP
compared/VBN
with/IN
theoretical/JJ
peptides/NNS
in/IN
the/DT
database/NN
search/VBP
strategy/NN
,/,
de/FW
novo/FW
sequencing/NN
,/,
which/WDT
is/VBZ
the/DT
direct/JJ
assignment/NN
of/IN
the/DT
amino/NN
acid/NN
sequence/NN
from/IN
the/DT
MS/MS/NN
spectrum/NN
,/,
can/MD
be/VB
pursued/VBN
when/WRB
the/DT
database/NN
is/VBZ
not/RB
available/JJ
./.
====================
Although/IN
de/FW
novo/FW
sequencing/NN
can/MD
be/VB
performed/VBN
manually/RB
,/,
the/DT
process/NN
is/VBZ
labor-intensive/JJ
and/CC
time-consuming/JJ
./.
====================
There/EX
are/VBP
several/JJ
software/JJ
packages/NNS
that/DT
can/MD
perform/VB
de/FW
novo/FW
sequencing/NN
directly/RB
on/IN
MS/MS/NN
data/NNS
,/,
including/VBG
Lutefisk/NN
(/(
http/NN
:/:
//www.hairyfatguy.com/lutefisk//JJ
)/)
,/,
Mascot/NNP
Distiller/NN
(/(
Matrix/NN
Science/NNP
)/)
,/,
and/CC
PEAKS/NN
(/(
Bioinformatics/NNS
Solutions/NNS
,/,
http/NN
:/:
//www.bioinformaticssolutions.com//JJ
)/)
[/(
30/CD
]/)
./.
====================
The/DT
peptide/NN
sequences/NNS
obtained/VBN
from/IN
de/FW
novo/FW
sequencing/NN
are/VBP
often/RB
compared/VBN
with/IN
the/DT
nonredundant/JJ
database/NN
of/IN
the/DT
National/JJ
Center/NN
for/IN
Biotechnology/NN
Information/NN
to/TO
establish/VB
the/DT
peptide/NN
identities/VBZ
with/IN
the/DT
Basic/JJ
Local/JJ
Alignment/JJ
Search/NN
Tool/NN
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/BLAST/NN
)/)
./.
====================
The/DT
BLAST/NN
search/VBP
compares/NNS
a/DT
partial/JJ
neuropeptide/NN
sequence/NN
against/IN
the/DT
database/NN
of/IN
a/DT
closely/RB
related/JJ
species/NNS
./.
====================
Quantitative/JJ
Neuropeptidomics/NNS
====================
MS-based/JJ
peptidomic/JJ
techniques/NNS
allow/VBP
for/IN
measuring/VBG
relative/JJ
levels/NNS
of/IN
peptides/NNS
in/IN
different/JJ
conditions/NNS
of/IN
the/DT
samples/NNS
,/,
as/IN
well/RB
as/IN
peptide/NN
identification/NN
./.
====================
Quantitation/NN
of/IN
peptides/NNS
based/VBN
on/IN
MS/NN
is/VBZ
generally/RB
achieved/VBN
either/CC
by/IN
stable/JJ
isotope/NN
labeling/NN
or/CC
label-free/JJ
approaches/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
[/(
5051/CD
]/)
./.
====================
In/IN
stable/JJ
isotope/NN
labeling/VBG
,/,
the/DT
relative/JJ
levels/NNS
of/IN
peptides/NNS
in/IN
two/CD
different/JJ
samples/NNS
are/VBP
typically/RB
examined/VBN
by/IN
labeling/VBG
the/DT
peptides/NNS
in/IN
one/CD
sample/NN
with/IN
a/DT
light/JJ
stable/JJ
isotope/NN
and/CC
those/DT
in/IN
the/DT
other/JJ
sample/JJ
with/IN
a/DT
heavy/JJ
stable/JJ
isotope/NN
;/:
the/DT
two/CD
samples/NNS
are/VBP
then/RB
combined/VBN
and/CC
analyzed/VBD
together/RB
./.
====================
The/DT
relative/JJ
levels/NNS
of/IN
the/DT
peptides/NNS
are/VBP
calculated/VBN
by/IN
the/DT
difference/NN
in/IN
the/DT
MS/NN
peaks/VBZ
(/(
peak/NN
intensity/NN
or/CC
peak/NN
area/NN
)/)
of/IN
the/DT
two/CD
samples/NNS
./.
====================
While/IN
the/DT
stable/JJ
isotopes/NNS
can/MD
be/VB
introduced/VBN
to/TO
the/DT
peptides/NNS
either/CC
metabolically/RB
or/CC
through/IN
chemical/JJ
reactions/NNS
,/,
isotope/NN
labeling/NN
through/IN
chemical/JJ
reactions/NNS
enables/VBZ
one/CD
to/TO
obtain/VB
quantitative/JJ
information/NN
from/IN
biological/JJ
samples/NNS
,/,
such/JJ
as/IN
brain/NN
tissues/NNS
,/,
for/IN
which/WDT
metabolic/JJ
labeling/NN
is/VBZ
not/RB
available/JJ
./.
====================
A/DT
number/NN
of/IN
different/JJ
isotopic/JJ
tags/NNS
,/,
including/VBG
acetic/JJ
anhydride/NN
,/,
succinic/JJ
anhydride/NN
,/,
and/CC
trimethylammonium/NN
butyrate/CC
(/(
TMAB/NN
)/)
,/,
have/VBP
been/VBN
used/VBN
for/IN
quantitative/JJ
analyses/NNS
of/IN
endogenous/JJ
peptides/NNS
in/IN
various/JJ
samples/NNS
and/CC
conditions/NNS
[/(
63452/CD
]/)
./.
====================
For/IN
example/NN
,/,
the/DT
TMAB/NN
tag/NN
was/VBD
used/VBN
to/TO
evaluate/VB
the/DT
relative/JJ
changes/NNS
of/IN
endogenous/JJ
peptides/NNS
in/IN
response/NN
to/TO
food/NN
intake/JJ
or/CC
drug/NN
treatment/NN
[/(
535455/CD
]/)
and/CC
to/TO
assess/VB
the/DT
role/NN
of/IN
protein/NN
convertase/VBP
1/3/CD
and/CC
2/CD
in/IN
the/DT
processing/NN
of/IN
the/DT
peptides/NNS
in/IN
mouse/NN
models/NNS
[/(
5657/CD
]/)
./.
====================
In/IN
label-free/JJ
methods/NNS
,/,
each/DT
sample/NN
is/VBZ
prepared/VBN
separately/RB
and/CC
then/RB
subjected/VBD
directly/RB
to/TO
individual/JJ
LC-MS/NN
or/CC
LC-MS/MS/NN
runs/NNS
,/,
followed/VBN
by/IN
comparisons/NNS
of/IN
either/CC
the/DT
mass/NN
spectral/JJ
peak/NN
intensities/NNS
of/IN
the/DT
detected/VBN
peptides/NNS
or/CC
the/DT
total/JJ
number/NN
of/IN
MS/MS/NN
spectra/NN
identified/VBD
for/IN
a/DT
peptide/NN
,/,
called/VBN
spectral/JJ
counting/VBG
[/(
51/CD
]/)
./.
====================
Since/IN
there/EX
is/VBZ
no/DT
limit/VB
to/TO
the/DT
number/NN
of/IN
samples/NNS
that/DT
can/MD
be/VB
compared/VBN
,/,
label-free/JJ
quantitation/NN
allows/VBZ
for/IN
the/DT
comparison/NN
of/IN
multiple/JJ
samples/NNS
or/CC
conditions/NNS
./.
====================
The/DT
approach/NN
has/VBZ
been/VBN
used/VBN
to/TO
measure/VB
the/DT
changes/NNS
in/IN
the/DT
levels/NNS
of/IN
neuropeptides/NNS
present/JJ
during/IN
the/DT
daytime/NN
and/CC
nighttime/RB
in/IN
the/DT
rat/NN
SCN/NN
[/(
5859/CD
]/)
and/CC
to/TO
examine/VB
the/DT
expression/NN
changes/NNS
of/IN
endogenous/JJ
peptides/NNS
involved/VBD
in/IN
the/DT
embryogenesis/NN
of/IN
Japanese/JJ
quail/RB
brains/NNS
[/(
60/CD
]/)
and/CC
the/DT
nucleus/NN
accumbens/VBZ
of/IN
morphine-dependent/JJ
rats/NNS
[/(
61/CD
]/)
./.
====================
In/IN
addition/NN
,/,
quantitative/JJ
peptidomic/JJ
analyses/NNS
based/VBN
on/IN
peak/NN
intensities/NNS
has/VBZ
enabled/VBN
us/PRP
to/TO
discover/RB
endogenous/JJ
peptides/NNS
associated/VBN
with/IN
repeated/VBN
exposure/NN
to/TO
amphetamine/VB
and/CC
with/IN
individual/JJ
variations/NNS
in/IN
sensitivity/NN
to/TO
the/DT
behavioral/JJ
effects/NNS
of/IN
cocaine/NN
in/IN
rat/NN
models/NNS
[/(
6263/CD
]/)
./.
====================
Neuropeptides/NNS
are/VBP
important/JJ
signaling/NN
molecules/NNS
that/WDT
are/VBP
involved/VBN
in/IN
many/JJ
kinds/NNS
of/IN
physiological/JJ
processes/NNS
,/,
including/VBG
addiction/NN
,/,
depression/NN
,/,
mood/NN
regulation/NN
,/,
and/CC
circadian/JJ
rhythms/NNS
./.
====================
Because/IN
of/IN
their/PRP$
biological/JJ
significance/NN
,/,
neuropeptides/NNS
have/VBP
become/VBN
key/JJ
targets/NNS
in/IN
drug/NN
discovery/NN
./.
====================
While/IN
immunological/JJ
techniques/NNS
,/,
such/JJ
as/IN
RIA/NN
and/CC
IHC/NN
,/,
require/VBP
a/DT
priori/JJ
knowledge/NN
of/IN
neuropeptides/NNS
and/CC
only/RB
detect/VB
peptide/NN
sequences/NNS
with/IN
known/VBN
structures/NNS
,/,
MS/NN
enables/VBZ
one/CD
to/TO
detect/VB
and/CC
identify/VBP
the/DT
precise/JJ
forms/NNS
of/IN
neuropeptides/NNS
without/IN
a/DT
priori/JJ
knowledge/NN
of/IN
peptide/NN
identity/NN
,/,
resulting/VBG
in/IN
the/DT
identification/NN
of/IN
previously/RB
unknown/JJ
neuropeptides/NNS
./.
====================
In/IN
addition/NN
,/,
MS-based/JJ
quantitative/JJ
analyses/NNS
of/IN
neuropeptides/NNS
based/VBN
on/IN
either/CC
stable/JJ
isotope/NN
labeling/NN
or/CC
label-free/JJ
methods/NNS
provide/VBP
information/NN
on/IN
the/DT
relative/JJ
levels/NNS
of/IN
neuropeptides/NNS
in/IN
different/JJ
physiological/JJ
conditions/NNS
,/,
which/WDT
can/MD
be/VB
helpful/JJ
in/IN
understanding/VBG
the/DT
function/NN
of/IN
the/DT
neuropeptides/NNS
./.
====================
Continuous/JJ
efforts/NNS
to/TO
implement/JJ
current/JJ
MS-based/JJ
peptidomics/NNS
techniques/NNS
for/IN
neuropeptide/NN
identification/NN
and/CC
quantitation/NN
are/VBP
expected/VBN
to/TO
provide/VB
more/RBR
profound/JJ
insights/NNS
into/IN
the/DT
neurochemical/JJ
communication/NN
of/IN
neurons/NNS
in/IN
various/JJ
physiological/JJ
processes/NNS
./.
====================
Bioactive/JJ
neuropeptide/NN
synthesis/NN
./.
====================
Adopted/JJ
from/IN
Fricker/NN
et/FW
al/JJ
./.
====================
Mass/NN
Spectrom/NN
Rev/NN
2006/CD
;/:
25:327-344/CD
,/,
with/IN
permission/NN
of/IN
John/NN
Wiley/NNP
and/CC
Sons/NNS
[/(
6/CD
]/)
./.
====================
A/DT
hypothetical/JJ
precursor/NN
is/VBZ
shown/VBN
to/TO
contain/VB
typical/JJ
processing/NN
sites/NNS
of/IN
Lys-Arg/NN
(/(
KR/NN
)/)
,/,
Arg-Arg/NN
(/(
RR/NN
)/)
,/,
or/CC
R-Xn-R/NN
,/,
where/WRB
n/NN
=/JJ
2/CD
,/,
4/CD
,/,
or/CC
6/CD
./.
====================
First/RB
,/,
a/DT
signal/NN
peptidase/NN
in/IN
the/DT
endoplasmic/JJ
reticulum/NN
removes/VBZ
the/DT
N-terminal/JJ
signal/NN
peptide/NN
,/,
and/CC
the/DT
precursor/NN
is/VBZ
routed/VBN
to/TO
the/DT
Golgi/NNP
apparatus/NN
and/CC
packaged/JJ
into/IN
dense-core/RB
secretory/JJ
vesicles/NNS
./.
====================
The/DT
prohormone/NN
convertase/NN
1/CD
,/,
2/CD
,/,
or/CC
5A/NN
cleaves/VBZ
the/DT
precursor/NN
to/TO
produce/VB
intermediates/NNS
that/DT
contain/VBP
C-terminal/JJ
K/NN
and/or/CC
R/NN
residues/NNS
./.
====================
Those/DT
basic/JJ
residues/NNS
are/VBP
removed/VBN
by/IN
carboxypeptidase/NN
E/NN
(/(
or/CC
D/NN
)/)
./.
====================
After/IN
removal/NN
of/IN
the/DT
basic/JJ
residues/NNS
,/,
peptides/NNS
with/IN
a/DT
C-terminal/JJ
glycine/NN
are/VBP
typically/RB
converted/VBD
to/TO
the/DT
amide/NN
by/IN
peptidyl-glycine/NN
α-amidating/VBG
monooxygenase/NN
./.
====================
In/IN
addition/NN
,/,
a/DT
number/NN
of/IN
other/JJ
post-translational/JJ
modifications/NNS
(/(
PTMs/NNS
)/)
,/,
including/VBG
N-terminal/JJ
acetylation/NN
,/,
phosphorylation/NN
,/,
and/CC
pyroglutamylation/NN
,/,
have/VBP
been/VBN
reported/VBN
./.
====================
Overall/RB
workflow/NN
of/IN
mass/NN
spectrometry/NN
(/(
MS/NN
)/)
-based/JJ
peptidomics/NNS
./.
====================
Adopted/JJ
from/IN
Schrader/NN
et/FW
al/JJ
./.
====================
EuPA/NN
Open/JJ
Proteom/NN
2014/CD
;/:
3:171-182/CD
,/,
according/VBG
to/TO
Creative/JJ
Commons/NNS
License/JJ
[/(
33/CD
]/)
./.
====================
Peptidomics/NNS
focuses/VBZ
on/IN
analyzing/VBG
endogenous/JJ
peptides/NNS
that/WDT
are/VBP
present/JJ
in/IN
biological/JJ
samples/NNS
,/,
including/VBG
brain/NN
tissue/NN
./.
====================
In/IN
contrast/NN
to/TO
bottom-up/DT
proteomics/NNS
studies/NNS
that/IN
involve/VBP
proteolytic/JJ
digestion/NN
,/,
it/PRP
is/VBZ
important/JJ
to/TO
minimize/VB
the/DT
activity/NN
of/IN
proteases/NNS
that/IN
may/MD
be/VB
present/JJ
in/IN
the/DT
samples/NNS
via/IN
heat/NN
or/CC
microwave/JJ
irradiation/NN
prior/JJ
to/TO
peptide/NN
extraction/NN
in/IN
the/DT
peptidomics/NNS
experiments/NNS
./.
====================
While/IN
the/DT
extracted/JJ
peptides/NNS
can/MD
be/VB
analyzed/VBN
directly/RB
by/IN
matrix-assisted/JJ
laser/NN
desorption/ionization/NN
(/(
MALDI/NN
)/)
-MS/NN
,/,
they/PRP
are/VBP
often/RB
separated/VBN
by/IN
reversed-phase/NN
chromatography/NN
or/CC
capillary/JJ
electrophoresis/NN
in/IN
order/NN
to/TO
reduce/VB
sample/JJ
complexity/NN
./.
====================
Then/RB
,/,
the/DT
peptides/NNS
are/VBP
analyzed/VBN
by/IN
MS/NN
in/IN
order/NN
to/TO
obtain/VB
amino/NN
acid/NN
sequence/NN
information/NN
of/IN
the/DT
peptides/NNS
without/IN
a/DT
priori/JJ
knowledge/NN
./.
====================
RP-HPLC/NN
,/,
reverse/JJ
phase-high/JJ
performance/NN
liquid/JJ
chromatography/NN
;/:
LC-ESI-MS/NN
,/,
liquid/JJ
chromatography/NN
electrospray/NN
ionization/NN
mass/NN
spectrometry/NN
./.
====================
Workflow/IN
of/IN
mass/NN
spectrometry/NN
(/(
MS/NN
)/)
-based/JJ
quantitation/NN
of/IN
endogenous/JJ
peptides/NNS
./.
====================
Romanova/NNP
et/FW
al/JJ
./.
====================
Curr/NN
Opin/NN
Chem/NNP
Biol/NNP
2013/CD
;/:
17:801-808/CD
,/,
with/IN
permission/NN
of/IN
Elsevier/NN
[/(
51/CD
]/)
./.
====================
Quantitation/NN
of/IN
endogenous/JJ
peptides/NNS
based/VBN
on/IN
MS/NN
is/VBZ
generally/RB
achieved/VBN
either/CC
by/IN
stable/JJ
isotope/NN
labeling/NN
(/(
A/NN
)/)
or/CC
label-free/JJ
approaches/NNS
(/(
B/NN
)/)
./.
====================
In/IN
stable/JJ
isotope/NN
labeling/NN
,/,
the/DT
endogenous/JJ
peptides/NNS
in/IN
two/CD
different/JJ
samples/NNS
are/VBP
labeled/VBN
with/IN
either/CC
a/DT
light/JJ
stable/JJ
isotope/NN
or/CC
a/DT
heavy/JJ
stable/JJ
isotope/NN
,/,
and/CC
the/DT
two/CD
samples/NNS
are/VBP
then/RB
combined/VBN
and/CC
analyzed/VBD
together/RB
./.
====================
The/DT
relative/JJ
levels/NNS
of/IN
the/DT
peptides/NNS
are/VBP
calculated/VBN
by/IN
the/DT
difference/NN
in/IN
the/DT
MS/NN
peaks/VBZ
(/(
peak/NN
intensity/NN
or/CC
peak/NN
area/NN
)/)
of/IN
the/DT
two/CD
samples/NNS
./.
====================
In/IN
label-free/JJ
quantitation/NN
,/,
each/DT
sample/NN
is/VBZ
prepared/VBN
separately/RB
and/CC
then/RB
subjected/VBD
to/TO
individual/JJ
liquid/JJ
chromatography/NN
(/(
LC/NN
)/)
-MS/NN
or/CC
LC–tandem/JJ
mass/NN
spectrometry/NN
(/(
MS/MS/NN
)/)
runs/VBZ
,/,
followed/VBN
by/IN
comparisons/NNS
of/IN
either/CC
the/DT
mass/NN
spectral/JJ
peak/NN
intensities/NNS
of/IN
the/DT
detected/VBN
peptides/NNS
or/CC
the/DT
total/JJ
number/NN
of/IN
MS/MS/NN
spectra/NN
identified/VBD
for/IN
a/DT
peptide/NN
,/,
called/VBN
spectral/JJ
counting/VBG
./.
====================
